ProShares UltraShort NASDAQ Biotechnology
9 hedge funds and large institutions have $1.88M invested in ProShares UltraShort NASDAQ Biotechnology in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 4 closing their positions.
186% more call options, than puts
Call options by funds: $689K | Put options by funds: $241K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
0.15% less ownership
Funds ownership: 0.68% → 0.53% (-0.15%)
25% less funds holding
Funds holding: 12 → 9 (-3)
29% less capital invested
Capital invested by funds: $2.62M → $1.88M (-$749K)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$259K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$86K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$14.1K |
| 4 |
AG
Advisor Group
Phoenix,
Arizona
|
+$11.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wolverine Trading
Chicago,
Illinois
|
-$267K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$242K |
| 3 |
Morgan Stanley
New York
|
-$110K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$74.8K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$41.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
1
Virtu Financial
New York
| $643K | +$259K | +1,437 | +58% |
|
|
HVC
2
Healthcare Value Capital
Woodcliff Lake,
New Jersey
| $514K | – | – | – |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $317K | -$74.8K | -415 | -18% |
|
|
4
Citadel Advisors
Miami,
Florida
| $252K | +$86K | +477 | +45% |
|
|
5
UBS Group
Zurich,
Switzerland
| $66K | +$14.1K | +78 | +24% |
|
|
6
Morgan Stanley
New York
| $42K | -$110K | -610 | -71% |
|
7
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| $29K | – | – | – |
|
|
AG
8
Advisor Group
Phoenix,
Arizona
| $10K | +$11.4K | +63 | New |
|
|
9
Simplex Trading
Chicago,
Illinois
| $2K | -$41.5K | -230 | -95% |
|
|
10
Wolverine Trading
Chicago,
Illinois
| – | -$267K | -1,481 | Closed |
|
|
11
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$242K | -1,340 | Closed |
|
12
Bank of America
Charlotte,
North Carolina
| – | -$24K | -125 | Closed |
|
|
FANJ
13
Financial Architects (New Jersey)
Marlton,
New Jersey
| – | -$1K | -4 | Closed |
|
BIS Hedge Fund Activity: Q3 2017 in Review
9 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q3 2017, worth a combined $1.88M — down 29% from $2.62M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of BIS and 1 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 3 added.
The largest buyer was Virtu Financial, adding an estimated $259K. The largest seller was Wolverine Trading, exiting entirely with an estimated $267K sold.
- 9 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q3 2017, down from 12 in Q2 2017.
- Funds reported $1.88M of ProShares UltraShort NASDAQ Biotechnology stock for Q3 2017, down 29% quarter-over-quarter.
- 1 fund opened new ProShares UltraShort NASDAQ Biotechnology positions in Q3 2017 and 4 closed out, a net change of -3 holders.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q3 2017 was Virtu Financial, an estimated $259K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q3 2017 was Wolverine Trading, an estimated $267K sold.
Based on aggregated 13F filings for Q3 2017.